Top Page
Prophase Labs
(NASDAQ:PRPH)
Prophase Labs (PRPH) vs. SPDR S&P 500 ETF (SPY)
Prophase Labs Business Overview & Revenue Model
Prophase Labs Earnings Call Summary
Prophase Labs Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.08M | 6.77M | 44.38M | 122.65M | 79.04M | 14.51M |
| Gross Profit | 2.06M | -150.00K | 16.24M | 70.65M | 32.81M | 4.61M |
| EBITDA | -24.81M | -32.34M | -14.83M | 28.73M | 11.39M | -1.49M |
| Net Income | -41.70M | -53.36M | -16.78M | 18.46M | 6.27M | -2.13M |
Balance Sheet | ||||||
| Total Assets | 65.70M | 63.20M | 91.93M | 87.65M | 89.30M | 31.41M |
| Cash, Cash Equivalents and Short-Term Investments | 405.00K | 678.00K | 4.74M | 17.44M | 17.51M | 8.46M |
| Total Debt | 7.68M | 24.57M | 18.46M | 6.96M | 14.90M | 14.72M |
| Total Liabilities | 58.84M | 55.85M | 42.54M | 24.02M | 30.67M | 20.85M |
| Stockholders Equity | 6.86M | 7.35M | 49.38M | 63.63M | 58.63M | 10.56M |
Cash Flow | ||||||
| Free Cash Flow | -22.75M | -18.44M | -14.50M | 24.63M | -17.85M | -4.28M |
| Operating Cash Flow | -22.99M | -17.54M | -11.35M | 28.55M | -13.62M | -2.59M |
| Investing Cash Flow | -40.00K | 2.42M | -1.37M | -2.08M | -19.67M | -1.02M |
| Financing Cash Flow | 9.66M | 14.19M | 5.76M | -26.02M | 35.13M | 9.99M |
Prophase Labs Technical Analysis
Prophase Labs Risk Analysis
Prophase Labs Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $21.11M | -0.76 | -50.23% | ― | -15.61% | -68.96% | |
47 Neutral | $13.54M | -29.32 | 0.27% | ― | 75.19% | ― | |
42 Neutral | $6.72M | -2.36 | -93.87% | ― | -0.74% | 81.49% | |
40 Neutral | $6.77M | -0.23 | -37.38% | ― | -22.60% | 53.82% | |
40 Underperform | $7.21M | -0.13 | -33.13% | ― | -7.80% | 90.17% | |
39 Underperform | $9.65M | ― | ― | ― | ― | ― |
Prophase Labs Corporate Events
ProPhase Labs, Inc. is a biotech and genomics company engaged in developing and commercializing novel drugs, dietary supplements, and diagnostics, with a focus on genomics sequencing technologies and consumer products. In its latest earnings report, ProPhase Labs highlighted a challenging financial quarter, with a net loss of $6.8 million for the three months ending September 30, 2025, compared to a loss of $6.6 million in the same period last year. The company’s revenues declined to $883,000 from $1.4 million a year ago, reflecting a decrease in COVID-19 diagnostic testing activities. Despite the financial setbacks, ProPhase Labs continues to advance its strategic initiatives, including the commercialization of its BE-Smart™ Esophageal Pre-Cancer Diagnostic Screening Test and the expansion of its genomics businesses. The company has also made significant strides in its genomics offerings through Nebula Genomics and DNA Complete, providing comprehensive genome sequencing services directly to consumers. Looking ahead, ProPhase Labs remains focused on recovering unpaid insurance claims from its discontinued COVID-19 testing operations and advancing its genomics and diagnostic product lines, with plans for broader commercialization in the coming year.
ProPhase Labs’ recent earnings call painted a mixed picture of optimism and challenges. While the company announced several promising developments, such as the Crown Medical collections and potential partnerships for its esophageal cancer test, these were tempered by financial constraints and a declining stock price. The company is actively pursuing strategic initiatives to address these issues and improve shareholder value.
On November 19, 2025, ProPhase Labs announced its strategic initiatives, including M&A discussions and the commercialization of the BE-Smart™ Esophageal Cancer Test following a landmark study. The company is also pursuing a $50 million collection initiative through Crown Medical, which has been appointed as Special Counsel to expedite litigation against insurance carriers. These efforts aim to unlock significant value for ProPhase, which it believes is not reflected in its current share price.
The most recent analyst rating on (PRPH) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on Prophase Labs stock, see the PRPH Stock Forecast page.
ProPhase Labs, Inc. has announced a delay in filing its Form 10-Q (Quarter Report) for the financial period ending September 30, 2025. The primary reason for the delay is the additional time required by the company and its auditor to ensure the accuracy and completeness of the report. The company expects to file the report within the 5-day extension period allowed by the SEC. Financially, the company has experienced significant changes due to the Chapter 11 reorganization of its subsidiaries, leading to a deconsolidation of these entities from its financial statements. This has resulted in a notable impact on its balance sheet, with a recognition of $43.7 million in investments and a payable of $27.7 million. The notification was signed by Ted Karkus, the Chairman and CEO, emphasizing the company’s commitment to compliance and transparency.
The most recent analyst rating on (PRPH) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on Prophase Labs stock, see the PRPH Stock Forecast page.
On October 9, 2025, ProPhase Labs, Inc. entered into an At-the-Market Sales Agreement with WestPark Capital, Inc., allowing the company to offer and sell shares of its common stock through the agent. This agreement, underpinned by the company’s effective registration statement and related prospectus, provides ProPhase Labs with flexibility in its stock offerings, potentially impacting its market presence and financial strategy. The agreement includes customary provisions and allows for termination by either party, reflecting a strategic move to manage its capital and shareholder interests.
The most recent analyst rating on (PRPH) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on Prophase Labs stock, see the PRPH Stock Forecast page.
On September 12, 2025, ProPhase Labs entered into a Strategic Advisory and Private Placement Agreement with ThinkEquity LLC to serve as its exclusive strategic advisor, placement agent, and investment banker. The agreement involves a proposed private placement of approximately $6 million in securities, with ThinkEquity receiving compensation in cash and warrants. This strategic move is part of ProPhase Labs’ digital asset treasury strategy, potentially impacting its operations and market positioning by involving significant crypto asset accumulation and board representation rights for ThinkEquity.
The most recent analyst rating on (PRPH) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on Prophase Labs stock, see the PRPH Stock Forecast page.
On September 9, 2025, ProPhase Labs held a Special Meeting of Stockholders where 63.54% of shares were voted. The stockholders approved several proposals including amendments to equity compensation plans, an increase in authorized shares, a share repurchase program, and changes to the company’s bylaws, indicating strategic adjustments to enhance operational flexibility and shareholder value.
The most recent analyst rating on (PRPH) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on Prophase Labs stock, see the PRPH Stock Forecast page.
ProPhase Labs’ recent earnings call painted a picture of both optimism and caution, reflecting a balance between promising future prospects and current financial hurdles. The company is poised for potential growth through strategic initiatives, yet faces challenges with stock performance and financial stability.
On August 27, 2025, ProPhase Labs, Inc. announced the termination of its Common Stock Purchase Agreement with Keystone Capital Partners, LLC, which was initially established on January 29, 2025. This agreement allowed ProPhase Labs to sell shares of its common stock to Keystone up to approximately $7.7 million. The termination, effective August 28, 2025, was executed at the company’s discretion without any penalties or fees, and there are no other material relationships between the two entities.
The most recent analyst rating on (PRPH) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on Prophase Labs stock, see the PRPH Stock Forecast page.